-
Information-Publications
-
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPsDetails
-
RNAi screens identify HES4 as a regulator of redox balance supporting pyrimidine synthesis and tumor growthDetails
-
Disruption of WSB2-mediated NOXA Degradation Induces Synthetic Lethality to Anti-apoptotic BCL-2 Family Protein InhibitorsDetails
-
SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitopeDetails
-
Salivary Gland Protective and Anti-Inflammation Effects of Genistein in Sjögren's Syndrome by Inhibiting Xist/Acsl4-Mediated Ferroptosis Following Binding to …Details
-
Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing ToolDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands